Your Messages Inbox
Your Article Summary
See Latest ArticlesClinical Evaluation of De Marco Formula as an Adjunctive Therapy for Infected Ischemic Diabetic Foot: A Prospective Randomized Controlled Trial
Canadian Journal of Clinical Pharmacology, 08/17/09
Duarte HA et al. – The treatment with DMF for 52 days as an adjuvant for the conventional therapy was associated with a lower need for major amputations. It was also well tolerated and safe.
Related Articles
Exploring the complex care of the diabetic foot ulcer
JAAPA, 10/30/09
Relevance Score: 70%
Effectiveness of insoles used for the prevention of ulceration in the neuropathic diabetic foot: a systematic review
Journal of Diabetes and its Complications, 10/29/09
Relevance Score: 69%
The treatment of diabetic foot infections: focus on ertapenem
Vascular Health and Risk Management, 11/09/09
Relevance Score: 68%
Treatment of nonhealing diabetic foot ulcers with a platelet-derived growth factor gene-activated matrix: Results of a Phase 12 trial
Wound Repair and Regeneration, 11/13/09
Relevance Score: 67%
Management of diabetic foot problems
Journal of Vascular Surgery, 11/03/09
Relevance Score: 67%
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Cytokinetics Announces Clinical Trial Data Regarding SB-743921 to be Presented at the 2009 American Society of Hematology Annual Meeting and Exposition
Cytokinetics, 12/01/09
Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09
Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials
The Lancet - Early Online Publication, 11/30/09
Article Search
Sponsor